<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30101142</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>15</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2296-2565</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>6</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in public health</Title>                <ISOAbbreviation>Front Public Health</ISOAbbreviation>            </Journal>            <ArticleTitle>Health Economic Evaluations of Cancer in Brazil: A Systematic Review.</ArticleTitle>            <Pagination>                <MedlinePgn>205</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2018.00205</ELocationID>            <Abstract>                <AbstractText><b>Background:</b> A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied.</AbstractText>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context. <b>Methods:</b> A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013). <b>Results:</b> Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO). <b>Conclusions:</b> There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Campolina</LastName>                    <ForeName>Alessandro G</ForeName>                    <Initials>AG</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>National Institute for Science and Technology for Health Technology Assessment (IATS/CNPq), Porto Alegre, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuba</LastName>                    <ForeName>Tania Y</ForeName>                    <Initials>TY</Initials>                    <AffiliationInfo>                        <Affiliation>Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Decimoni</LastName>                    <ForeName>Tassia C</ForeName>                    <Initials>TC</Initials>                    <AffiliationInfo>                        <Affiliation>Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Leandro</LastName>                    <ForeName>Roseli</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Diz</LastName>                    <ForeName>Maria Del Pilar Estevez</ForeName>                    <Initials>MDPE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Novaes</LastName>                    <ForeName>Hillegonda M D</ForeName>                    <Initials>HMD</Initials>                    <AffiliationInfo>                        <Affiliation>National Institute for Science and Technology for Health Technology Assessment (IATS/CNPq), Porto Alegre, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>de Soárez</LastName>                    <ForeName>Patrícia C</ForeName>                    <Initials>PC</Initials>                    <AffiliationInfo>                        <Affiliation>National Institute for Science and Technology for Health Technology Assessment (IATS/CNPq), Porto Alegre, Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Public Health</MedlineTA>            <NlmUniqueID>101616579</NlmUniqueID>            <ISSNLinking>2296-2565</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2012 Jul 15;131(2):E96-104</RefSource>                <PMID Version="1">21964797</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Value Health. 2011 Jun;14(4):458-64</RefSource>                <PMID Version="1">21669370</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Manag Care Spec Pharm. 2014 Nov;20(11):1086-92</RefSource>                <PMID Version="1">25351969</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Saude Publica. 2010 Aug;44(4):620-8</RefSource>                <PMID Version="1">20676553</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Prev Med. 2016 Feb;50(2):241-8</RefSource>                <PMID Version="1">26470806</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int Braz J Urol. 2003 May-Jun;29(3):234-7</RefSource>                <PMID Version="1">15745527</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Econ. 2008;11(2):311-25</RefSource>                <PMID Version="1">19450088</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Assoc Med Bras (1992). 2013 Sep-Oct;59(5):442-51</RefSource>                <PMID Version="1">24041909</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Vaccine. 2012 Jul 6;30(32):4866-71</RefSource>                <PMID Version="1">22652405</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Public Health. 2018 Feb 28;6:52</RefSource>                <PMID Version="1">29541630</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2011 Aug 1;129(3):671-9</RefSource>                <PMID Version="1">20886598</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Assoc Med Bras (1992). 2009 Jul-Aug;55(4):410-5</RefSource>                <PMID Version="1">19750307</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Assoc Med Bras (1992). 2009 Sep-Oct;55(5):535-40</RefSource>                <PMID Version="1">19918652</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Transl Oncol. 2013 Jan;15(1):9-19</RefSource>                <PMID Version="1">23180344</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cad Saude Publica. 2011 Aug;27(8):1529-36</RefSource>                <PMID Version="1">21877001</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Value Health. 2016 Dec;19(8):929-935</RefSource>                <PMID Version="1">27987642</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Econ. 2008;11(3):383-96</RefSource>                <PMID Version="1">19450094</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Dig Dis Sci. 2008 Dec;53(12):3103-11</RefSource>                <PMID Version="1">18523886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2013 Jan 1;19(1):6-11</RefSource>                <PMID Version="1">23288370</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Econ. 2010 Mar;19(3):350-64</RefSource>                <PMID Version="1">19378354</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>HIV Clin Trials. 2006 Jul-Aug;7(4):194-202</RefSource>                <PMID Version="1">17065031</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Public Health. 2002;23:115-34</RefSource>                <PMID Version="1">11910057</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer (Dove Med Press). 2012 Nov 13;4:173-82</RefSource>                <PMID Version="1">24367204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Bras Ginecol Obstet. 2010 Aug;32(8):386-92</RefSource>                <PMID Version="1">21180875</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Cir Bras. 2012 May;27(5):311-4</RefSource>                <PMID Version="1">22666744</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Infect Dis. 2012 Oct 09;12:250</RefSource>                <PMID Version="1">23046886</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cien Saude Colet. 2012 Jan;17(1):215-22</RefSource>                <PMID Version="1">22218554</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Mar 10;28(8):1415-21</RefSource>                <PMID Version="1">20142591</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Indian J Cancer. 2009 Jul-Sep;46(3):184-9</RefSource>                <PMID Version="1">19574668</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Panam Salud Publica. 2010 Oct;28(4):244-8</RefSource>                <PMID Version="1">21152711</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2015 Oct;16(14):1405-38</RefSource>                <PMID Version="1">26522157</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2012 Jan;13(1):14-5</RefSource>                <PMID Version="1">22225717</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2010 Jan 20;102(2):82-8</RefSource>                <PMID Version="1">20056956</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Ther. 2011 Nov;33(11):1769-1780.e2</RefSource>                <PMID Version="1">22019346</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>An Bras Dermatol. 2009 Jul;84(3):237-43</RefSource>                <PMID Version="1">19668936</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int Braz J Urol. 2003 Mar-Apr;29(2):127-30; discussion 130-2</RefSource>                <PMID Version="1">15745495</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Technol Assess Health Care. 2014 Oct;30(4):381-93</RefSource>                <PMID Version="1">25393627</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Chest. 1999 Jun;115(6):1494-9</RefSource>                <PMID Version="1">10378539</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Eval Clin Pract. 2010 Dec;16(6):1198-202</RefSource>                <PMID Version="1">20695955</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cad Saude Publica. 2012 Nov;28(11):2043-52</RefSource>                <PMID Version="1">23147946</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>An Bras Dermatol. 2011 Jul-Aug;86(4):657-62</RefSource>                <PMID Version="1">21987129</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arq Neuropsiquiatr. 1992 Mar;50(1):91-8</RefSource>                <PMID Version="1">1307485</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Assoc Med Bras (1992). 2008 Nov-Dec;54(6):494-9</RefSource>                <PMID Version="1">19197525</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Head Neck. 2011 Aug;33(8):1199-205</RefSource>                <PMID Version="1">21755563</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Saude Publica. 2011 Jun;45(3):575-82</RefSource>                <PMID Version="1">21519723</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Support Care Cancer. 2003 Jun;11(6):356-61</RefSource>                <PMID Version="1">12720070</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Gastroenterol Latinoam. 2001 Mar;31(1):13-22</RefSource>                <PMID Version="1">11370175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bull World Health Organ. 2016 Dec 1;94(12):925-930</RefSource>                <PMID Version="1">27994285</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Appl Health Econ Health Policy. 2014 Oct;12(5):497-510</RefSource>                <PMID Version="1">25060829</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2010;15 Suppl 1:73-9</RefSource>                <PMID Version="1">20237221</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacoeconomics. 2008;26(1):17-32</RefSource>                <PMID Version="1">18088156</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rev Assoc Med Bras (1992). 2010 Mar-Apr;56(2):186-91</RefSource>                <PMID Version="1">20498993</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Brazil</Keyword>            <Keyword MajorTopicYN="N">cost-benefit analysis</Keyword>            <Keyword MajorTopicYN="N">costs and cost analysis</Keyword>            <Keyword MajorTopicYN="N">health care costs</Keyword>            <Keyword MajorTopicYN="N">neoplasms</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30101142</ArticleId>            <ArticleId IdType="doi">10.3389/fpubh.2018.00205</ArticleId>            <ArticleId IdType="pmc">PMC6072849</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>